1. Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children.
- Author
-
Johannes Holle, Marietta Kirchner, Jürgen Okun, Aysun K Bayazit, Lukasz Obrycki, Nur Canpolat, Ipek Kaplan Bulut, Karolis Azukaitis, Ali Duzova, Bruno Ranchin, Rukshana Shroff, Cengiz Candan, Jun Oh, Günter Klaus, Francesca Lugani, Charlotte Gimpel, Rainer Büscher, Alev Yilmaz, Esra Baskin, Hakan Erdogan, Ariane Zaloszyc, Gül Özcelik, Dorota Drozdz, Augustina Jankauskiene, Francois Nobili, Anette Melk, Uwe Querfeld, Franz Schaefer, and C Study Consortium
- Subjects
Medicine ,Science - Abstract
The uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (pCS) accumulate in patients with chronic kidney disease (CKD) as a consequence of altered gut microbiota metabolism and a decline in renal excretion. Despite of solid experimental evidence for nephrotoxic effects, the impact of uremic toxins on the progression of CKD has not been investigated in representative patient cohorts. In this analysis, IS and pCS serum concentrations were measured in 604 pediatric participants (mean eGFR of 27 ± 11 ml/min/1.73m2) at enrolment into the prospective Cardiovascular Comorbidity in Children with CKD study. Associations with progression of CKD were analyzed by Kaplan-Meier analyses and Cox proportional hazard models. During a median follow up time of 2.2 years (IQR 4.3-0.8 years), the composite renal survival endpoint, defined as 50% loss of eGFR, or eGFR
- Published
- 2020
- Full Text
- View/download PDF